Search

Your search keyword '"KREMER, JOEL M."' showing total 975 results
Start Over Author "KREMER, JOEL M."
975 results on '"KREMER, JOEL M."'

7. Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis

Author

Kavanaugh, Arthur, Singh, Rakesh, Karki, Chitra, Etzel, Carol J, Kremer, Joel M, Greenberg, Jeffrey D, and Griffith, Jenny

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Rare Diseases, Pain Research, Autoimmune Disease, Rheumatoid Arthritis, Clinical Research, Chronic Pain, Arthritis, Inflammatory and immune system, Good Health and Well Being, Arthritis, Psoriatic, Arthritis, Rheumatoid, Biological Products, Female, Humans, Male, Middle Aged, Prospective Studies, Quality of Life, Retrospective Studies, Biologics, Disease burden, Psoriatic arthritis, Rheumatoid arthritis, Arthritis & Rheumatology, Clinical sciences, Immunology, Allied health and rehabilitation science
Abstract

To compare disease burden and biologic use among psoriatic arthritis (PsA) or rheumatoid arthritis (RA) patients recruited to the Corrona registry. Retrospective study of patients with PsA or RA enrolled in Corrona between January 2002 and March 2013 and grouped in 2-year intervals. Clinical outcomes and biologic use were assessed. Biologic use increased over time in both cohorts, with 62 and 52% of patients with PsA and RA, respectively, receiving biologics by 2012-2013. However, 25 and 35% of patients with PsA and RA, respectively, continued to experience moderate/high disease activity. Overall, the progressive increase in biologic use accompanied progressive decreases in Clinical Disease Activity Index (from 14.2 to 10.4 for RA, and 12.4 to 8.1 for PsA) and mean Health Assessment Questionnaire score (from 0.36 to 0.34, and 0.3 to 0.24). Mean patient pain, the proportion of patients reporting morning stiffness, and the mean duration of morning stiffness remained similar for both cohorts. PsA and RA treated in the rheumatology setting had a comparable impact on patient quality of life and functional ability. Disease burden improved with increased biologic utilization in both groups; however, moderate/severe disease remains in a significant proportion of PsA and RA patients.

Published
2018

9. Sex differences in gout characteristics: tailoring care for women and men

Author

Harrold, Leslie R, Etzel, Carol J, Gibofsky, Allan, Kremer, Joel M, Pillinger, Michael H, Saag, Kenneth G, Schlesinger, Naomi, Terkeltaub, Robert, Cox, Vanessa, and Greenberg, Jeffrey D

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Aging, Nutrition, Prevention, Management of diseases and conditions, 7.1 Individual care needs, Good Health and Well Being, Aged, Aged, 80 and over, Cohort Studies, Cross-Sectional Studies, Diabetes Mellitus, Diuretics, Female, Gout, Humans, Hypertension, Male, Middle Aged, Obesity, Precision Medicine, Prospective Studies, Sex Characteristics, Comorbidity, Gender, Quality of Care, Orthopedics, Clinical sciences, Allied health and rehabilitation science, Sports science and exercise
Abstract

BackgroundTo characterize the differences between women and men with gout.MethodsWe analyzed a US national cohort of gout patients cared for by rheumatologists.ResultsCompared with the 1012 men with gout, women with gout (n = 262) were older (71 vs. 61 years, p

Published
2017

10. A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor-α Inhibitors: The NETWORK-004 Prospective Observational Study

Author

Cohen, Stanley, Wells, Alvin F., Curtis, Jeffrey R., Dhar, Rajat, Mellors, Theodore, Zhang, Lixia, Withers, Johanna B., Jones, Alex, Ghiassian, Susan D., Wang, Mengran, Connolly-Strong, Erin, Rapisardo, Sarah, Gatalica, Zoran, Pappas, Dimitrios A., Kremer, Joel M., Saleh, Alif, and Akmaev, Viatcheslav R.

Published
2021
Full Text
View/download PDF

20. Prevalence of Fibromyalgia and Widespread Pain in Psoriatic Arthritis: Association With Disease Severity Assessment in a Large US Registry.

Author

Mease, Philip, Reed, George, Ogdie, Alexis, Pappas, Dimitrios A., and Kremer, Joel M.

Subjects
ETIOLOGY of diseases, PSORIATIC arthritis, BODY mass index, PAIN measurement, NERVE fibers, FIBROMYALGIA
Abstract

Objective: The classic conception of pain etiology in rheumatologic disease is nociceptive pain—tissue injury and inflammation signaling through peripheral and central nerve fibers. But this can be mixed with other pain etiologies, including nociplastic, which is augmented pain experience due to central sensitization. The pain of fibromyalgia (FM) is nociplastic, occurs in 10% to 30% of patients with rheumatologic disease, and its presence can influence disease severity assessment. The objective of our study was to (1) ascertain the prevalence of FM and widespread pain (WP) in the CorEvitas psoriatic arthritis (PsA) registry as assessed by the Widespread Pain Index (WPI) and Symptom Severity Scale (SSS) questionnaires; (2) characterize the demographic and clinical factors associated with FM and WP; and (3) ascertain the association of FM and WP on the Clinical Disease Activity in Psoriatic Arthritis (cDAPSA) score and other disease activity measures. Methods: PsA registry patients completing the WPI/SSS questionnaires since May 2020, at their most recent visit recorded in the registry, were analyzed. Results: The analysis included 1,823 patients with PsA; 11.1% fulfilled the FM definition and 20.6% fulfilled the WP definition. Several factors were associated with the FM definition, including female sex, depression and/or anxiety, impaired function, increased body mass index, and increased number of comorbidities. cDAPSA, patient pain and global assessment, and tender joint count were twice as severe in patients with FM compared to those without. Conclusion: FM prevalence is elevated in PsA and is associated with elevated disease measures, confounding reliable disease assessment for treat‐to‐target goals. Identification of FM as an influential contextual factor in disease assessment is recommended. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

Author

Ahmed, Khalid, Alper, Jeffrey, Barkham, Nichol, Bennett, Ralph E., García, Francisco Javier Blanco, Alonso, Ricardo Blanco, Blumstein, Howard B., Brooks, Michael S., Burmester, Gerd-Rüdiger, Cagnoli, Patricia, Caldron, Paul H., Cantagrel, Alain, Chen, Der-Yuan, Churchill, Melvin A., Jr, Codding, Christine E., Combe, Benard, Deane, Peter M.G., Del Giudice, Jose, Deodhar, Atul A., Dhar, Rajat K., Dokoupilova, Eva, Egan, Rita M., Everding, Andrea, Galíndez, Eva, Genovese, Mark, Goddard, David H., Gottlieb, Alice, Goupille, Philippe, Griffin, Robert M., Gupta, Ramesh C., Hall, Stephen, Hatti, Kalpita, Howell, Mary P., Huang, Yu-Huei, Jajoo, Ramina, Janssen, Namieta M., Kiltz, Uta, Kivitz, Alan J., Klein, Steven J., Korkosz, Mariusz P., Kotha, Roshan, Kremer, Joel M., Lue, Cummins, de la Fuente, José Luis Marenco, Marzo-Ortega, Helena, Masmitja, Jordi Gratacós, Mease, Philip J., Meroni, Pier Luigi, Mueller, Eric C., Nandagudi, Anupama C., Nash, Peter, Fernández-Nebro, Antonio, Neuwelt, Clark M., Orbai, Ana Maria, Oza, Meera R., Parks, Deborah L., Pattanaik, Debendra, Rell-Bakalarska, Maria E., Rosmarin, David, Roussou, Euthalia, Rychlewska-Hanczewksa, Anna I., Sikes, David H., Stack, Michael T., Sunkureddi, Prashanth, Tahir, Hasan, Thaçi, Diamant, Tsai, Tsen-Fang, Turkiewicz, Anthony M., Unger, Leonore, Cabello, Raúl Veiga, Wagner, Ulf, Wei, Cheng-Chung, Wells, Alvin F., Youssef, Peter, Zielinska, Agnieszka, Kirkham, Bruce, Okada, Masato, Rahman, Proton, Burmester, Gerd-Ruediger, Adams, David H, Kerr, Lisa, Lee, Chin, and Shuler, Catherine L

Published
2017
Full Text
View/download PDF

29. Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: a multinational cross-sectional study

Author

Pappas, Dimitrios A., Nyberg, Fredrik, Kremer, Joel M., Lampl, Kathy, Reed, George W., Horne, Laura, Ho, Meilien, Onofrei, Alina, Malaviya, Anand N., Rillo, Oscar L., Radominski, Sebastiao C., Gal, Janos, Gibofsky, Allan, Popkova, Tatiana V., Laurindo, Leda, Kerzberg, Eduardo M., Zahora, Roman, Pons-Estel, Bernado A., Curtis, Jeffrey R., Furst, Daniel E., and Greenberg, Jeffrey D.

Published
2018
Full Text
View/download PDF

31. Molecular profiling of rheumatoid arthritis patients reveals an association between innate and adaptive cell populations and response to anti-tumor necrosis factor

Author

Farutin, Victor, Prod’homme, Thomas, McConnell, Kevin, Washburn, Nathaniel, Halvey, Patrick, Etzel, Carol J., Guess, Jamey, Duffner, Jay, Getchell, Kristen, Meccariello, Robin, Gutierrez, Bryan, Honan, Christopher, Zhao, Ganlin, Cilfone, Nicholas A., Gunay, Nur Sibel, Hillson, Jan L., DeLuca, David S., Saunders, Katherine C., Pappas, Dimitrios A., Greenberg, Jeffrey D., Kremer, Joel M., Manning, Anthony M., Ling, Leona E., and Capila, Ishan

Published
2019
Full Text
View/download PDF

32. Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions:an update

Author

Aletaha, Daniel, Kerschbaumer, Andreas, Kastrati, Kastriot, Dejaco, Christian, Dougados, Maxime, McInnes, Iain B., Sattar, Naveed, Stamm, Tanja A., Takeuchi, Tsutomu, Trauner, Michael, Van Der Heijde, Désirée, Voshaar, Marieke, Winthrop, Kevin L., Ravelli, Angelo, Betteridge, Neil, Burmester, Gerd Rüdiger R., Bijlsma, Johannes W.J., Bykerk, Vivian, Caporali, Roberto, Choy, Ernest H., Codreanu, Catalin, Combe, Bernard, Crow, Mary K., De Wit, Maarten, Emery, Paul, Fleischmann, Roy M., Gabay, Cem, Hetland, Merete Lund, Hyrich, Kimme L., Iagnocco, Annamaria, Isaacs, John D., Kremer, Joel M., Mariette, Xavier, Merkel, Peter, Mysler, Eduardo F., Nash, Peter, Nurmohamed, Michael T., Pavelka, Karel, Poor, Gyula, Rubbert-Roth, Andrea, Schulze-Koops, Hendrik, Strangfeld, Anja, Tanaka, Yoshiya, Smolen, Josef S., Aletaha, Daniel, Kerschbaumer, Andreas, Kastrati, Kastriot, Dejaco, Christian, Dougados, Maxime, McInnes, Iain B., Sattar, Naveed, Stamm, Tanja A., Takeuchi, Tsutomu, Trauner, Michael, Van Der Heijde, Désirée, Voshaar, Marieke, Winthrop, Kevin L., Ravelli, Angelo, Betteridge, Neil, Burmester, Gerd Rüdiger R., Bijlsma, Johannes W.J., Bykerk, Vivian, Caporali, Roberto, Choy, Ernest H., Codreanu, Catalin, Combe, Bernard, Crow, Mary K., De Wit, Maarten, Emery, Paul, Fleischmann, Roy M., Gabay, Cem, Hetland, Merete Lund, Hyrich, Kimme L., Iagnocco, Annamaria, Isaacs, John D., Kremer, Joel M., Mariette, Xavier, Merkel, Peter, Mysler, Eduardo F., Nash, Peter, Nurmohamed, Michael T., Pavelka, Karel, Poor, Gyula, Rubbert-Roth, Andrea, Schulze-Koops, Hendrik, Strangfeld, Anja, Tanaka, Yoshiya, and Smolen, Josef S.

Published
2023

33. Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update

Author

MS Reumatologie/Immunologie/Infectie, Infection & Immunity, Aletaha, Daniel, Kerschbaumer, Andreas, Kastrati, Kastriot, Dejaco, Christian, Dougados, Maxime, McInnes, Iain B., Sattar, Naveed, Stamm, Tanja A., Takeuchi, Tsutomu, Trauner, Michael, Van Der Heijde, Désirée, Voshaar, Marieke, Winthrop, Kevin L., Ravelli, Angelo, Betteridge, Neil, Burmester, Gerd Rüdiger R., Bijlsma, Johannes W.J., Bykerk, Vivian, Caporali, Roberto, Choy, Ernest H., Codreanu, Catalin, Combe, Bernard, Crow, Mary K., De Wit, Maarten, Emery, Paul, Fleischmann, Roy M., Gabay, Cem, Hetland, Merete Lund, Hyrich, Kimme L., Iagnocco, Annamaria, Isaacs, John D., Kremer, Joel M., Mariette, Xavier, Merkel, Peter A., Mysler, Eduardo F., Nash, Peter, Nurmohamed, Michael T., Pavelka, Karel, Poor, Gyula, Rubbert-Roth, Andrea, Schulze-Koops, Hendrik, Strangfeld, Anja, Tanaka, Yoshiya, Smolen, Josef S., MS Reumatologie/Immunologie/Infectie, Infection & Immunity, Aletaha, Daniel, Kerschbaumer, Andreas, Kastrati, Kastriot, Dejaco, Christian, Dougados, Maxime, McInnes, Iain B., Sattar, Naveed, Stamm, Tanja A., Takeuchi, Tsutomu, Trauner, Michael, Van Der Heijde, Désirée, Voshaar, Marieke, Winthrop, Kevin L., Ravelli, Angelo, Betteridge, Neil, Burmester, Gerd Rüdiger R., Bijlsma, Johannes W.J., Bykerk, Vivian, Caporali, Roberto, Choy, Ernest H., Codreanu, Catalin, Combe, Bernard, Crow, Mary K., De Wit, Maarten, Emery, Paul, Fleischmann, Roy M., Gabay, Cem, Hetland, Merete Lund, Hyrich, Kimme L., Iagnocco, Annamaria, Isaacs, John D., Kremer, Joel M., Mariette, Xavier, Merkel, Peter A., Mysler, Eduardo F., Nash, Peter, Nurmohamed, Michael T., Pavelka, Karel, Poor, Gyula, Rubbert-Roth, Andrea, Schulze-Koops, Hendrik, Strangfeld, Anja, Tanaka, Yoshiya, and Smolen, Josef S.

Published
2023

34. Anti-citrullinated protein antibody profiles predict changes in disease activity in patients with rheumatoid arthritis initiating biologics.

Author

Aripova, Nozima, Kremer, Joel M, Pappas, Dimitrios A, Reed, George, England, Bryant R, Robinson, Bill H, Curtis, Jeffrey R, Thiele, Geoffrey M, and Mikuls, Ted R

Subjects
*BIOTHERAPY, *AUTOANTIBODIES, *DRUG efficacy, *STATISTICS, *SCIENTIFIC observation, *CONFIDENCE intervals, *ANTI-inflammatory agents, *MULTIVARIATE analysis, *HEALTH outcome assessment, *REGRESSION analysis, *TREATMENT effectiveness, *RHEUMATOID arthritis, *FACTOR analysis, *DESCRIPTIVE statistics, *RESEARCH funding, *ODDS ratio, *LONGITUDINAL method, *ABATACEPT
Abstract

Objectives To determine whether an expanded antigen-specific ACPA profile predicts changes in disease activity in patients with RA initiating biologics. Methods The study included participants from a prospective, non-randomized, observational RA cohort. For this sub-study, treatment groups of interest included biologic-naïve initiating anti-TNF, biologic-exposed initiating non-TNF, and biologic-naïve initiating abatacept. ACPAs to 25 citrullinated peptides were measured using banked enrolment serum. Principal component analysis (PCA) was performed and associations of resulting principal component (PC) scores (in quartiles) and anti-CCP3 antibody (≤15, 16–250 or >250 U/ml) with EULAR (good/moderate/none) treatment response at 6 months were examined using adjusted ordinal regression models. Results Participants (n  = 1092) had a mean age of 57 (13) years and 79% were women. At 6 months, 68.5% achieved a moderate/good EULAR response. There were three PCs that cumulatively explained 70% of variation in ACPA values. In models including the three components and anti-CCP3 antibody category, only PC1 and PC2 were associated with treatment response. The highest quartile for PC1 (odds ratio [OR] 1.76; 95% CI: 1.22, 2.53) and for PC2 (OR 1.74; 95% CI: 1.23, 2.46) were associated with treatment response after multivariable adjustment. There was no evidence of interaction between PCs and treatment group in EULAR responses (P -value for interaction >0.1). Conclusion An expanded ACPA profile appears to be more strongly associated with biologic treatment response in RA than commercially available anti-CCP3 antibody levels. However, further enhancements to PCA will be needed to effectively prioritize between different biologics available for the treatment of RA. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

44. Rare, Low-Frequency, and Common Variants in the Protein-Coding Sequence of Biological Candidate Genes from GWASs Contribute to Risk of Rheumatoid Arthritis

Author

Diogo, Dorothée, Kurreeman, Fina, Stahl, Eli A., Liao, Katherine P., Gupta, Namrata, Greenberg, Jeffrey D., Rivas, Manuel A., Hickey, Brendan, Flannick, Jason, Thomson, Brian, Guiducci, Candace, Ripke, Stephan, Adzhubey, Ivan, Barton, Anne, Kremer, Joel M., Alfredsson, Lars, Sunyaev, Shamil, Martin, Javier, Zhernakova, Alexandra, Bowes, John, Eyre, Steve, Siminovitch, Katherine A., Gregersen, Peter K., Worthington, Jane, Klareskog, Lars, Padyukov, Leonid, Raychaudhuri, Soumya, and Plenge, Robert M.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results